Anosmia Market, by Type (Idiopathic Anosmia and Congenital Anosmia), by Treatment (Therapies (Nasal Endoscopy and Imaging) and Medications (Decongestants, Antihistamines, and Steroid Nasal Sprays)), and by Region (North America, Latin America, Europe, Asi

Anosmia Market, by Type (Idiopathic Anosmia and Congenital Anosmia), by Treatment (Therapies (Nasal Endoscopy and Imaging) and Medications (Decongestants, Antihistamines, and Steroid Nasal Sprays)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Anosmia, the clinical term for the inability to smell. This disorder impair the ability to sense odors in the environment, as well as hinder the quality of life related to social interactions, eating, and feelings of well-being. It is a severe disability, affected genetically or accidentally, resulting in total/partial absence of olfactory guidance.
Market Dynamics
Rising anosmia cases is the major factor that is expected to drive growth of the global anosmia market during the forecast period. For instance, according to an article published by the National Institute on Deafness and Other Communication Disorders in February 2021, around 3% of U.S. populace have anosmia i.e.no sense of smell.
Market players are focusing on research and development activities for offering novel products for the treatment anosmia, which is expected to drive the market growth over the forecast period. For instance, in July 2020, Zydus Cadila received the U.S. Food & Drug Administration (U.S. FDA) approval for its supplemental abbreviated new drug application (SANDA) for Doxycycline Injection USP, 100 mg/vial, which seems to improve respiratory symptoms and anosmia
Key features of the study:
This report provides in-depth analysis of the global anosmia market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global anosmia market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Mylan N.V., Pfizer Inc., Atom Pharma, RANBAXY LABORATORIES LIMITED, Alde Medi Impex, GlaxoSmithkline plc, Sandoz (Novasrtis AG), Inke S.A., Taj Pharmaceuticals Limited, and Sanofi, amongst others.
Insights from this report would allow marketers and management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global anosmia market report caters to various stakeholders in this industry including investors, suppliers, anosmia manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global anosmia market.

Detailed Segmentation
Global Anosmia Market, By Type
Idiopathic Anosmia
Congenital Anosmia
Global Anosmia Market, By Treatment
Therapies
Nasal Endoscopy
Imaging
Medications
Decongestants
Antihistamines
Steroid Nasal Sprays
Global Anosmia Market, By Region
North America
By Country
U.S.
Canada
By Type
Idiopathic Anosmia
Congenital Anosmia
By Treatment
Therapies
Nasal Endoscopy
Imaging
Medications
Decongestants
Antihistamines
Steroid Nasal Sprays
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Type
Idiopathic Anosmia
Congenital Anosmia
By Treatment
Therapies
Nasal Endoscopy
Imaging
Medications
Decongestants
Antihistamines
Steroid Nasal Sprays
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Type
Idiopathic Anosmia
Congenital Anosmia
By Treatment
Therapies
Nasal Endoscopy
Imaging
Medications
Decongestants
Antihistamines
Steroid Nasal Sprays
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Type
Idiopathic Anosmia
Congenital Anosmia
By Treatment
Therapies
Nasal Endoscopy
Imaging
Medications
Decongestants
Antihistamines
Steroid Nasal Sprays
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Type
Idiopathic Anosmia
Congenital Anosmia
By Treatment
Therapies
Nasal Endoscopy
Imaging
Medications
Decongestants
Antihistamines
Steroid Nasal Sprays
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Type
Idiopathic Anosmia
Congenital Anosmia
By Treatment
Therapies
Nasal Endoscopy
Imaging
Medications
Decongestants
Antihistamines
Steroid Nasal Sprays
Company Profiles
Mylan N.V.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Pfizer Inc.
Atom Pharma
RANBAXY LABORATORIES LIMITED
Alde Medi Impex
GlaxoSmithkline plc
Sandoz (Novasrtis AG)
Inke S.A.
Taj Pharmaceuticals Limited
Sanofi

“*” marked represents similar segmentation in other categories in the respective section.